Back to search
FDAFDA · Food and drugs·Recall number D-0081-2018

Urin D/S Tablets Methenamine 81.6 mg, Sodium Biphosphate 40.8 mg, Phenyl Salicylate 36.2 mg, Methylene Blue 10.8 mg, Hyoscyamine Sulfate 0.12 mg, Rx Only, 100-count bottle, Manufactured For: Llorens Pharmaceutical Corp., International Division, Miami, FL 33166. NDC: 54859-701-10

Published November 22, 2017 · Recall initiated: September 5, 2017

Summary

FDA records drug Class II recall D-0081-2018, published November 22, 2017 and initiated September 5, 2017. Recalling firm: Llorens Pharmaceutical Corp.; Status: Terminated; Reported quantity: 19232 bottles; Lot: Lots: 22811601, 22811602, Exp. 05/18; 202U1601 Exp. 11/18. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Superpotent Drug: Subpotent Drug. FDA analysis found this product to be Out of Specification for assay which could result in either Subpotent and/or Superpotent tablets.

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Llorens Pharmaceutical Corp.
Distributor
Puerto Rico
Lot
Lots: 22811601, 22811602, Exp. 05/18; 202U1601 Exp. 11/18
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Urin D/S Tablets Methenamine 81.6 mg, Sodium Biphosphate 40.8 mg, Phenyl Salicylate 36.2 mg, Methylene Blue 10.8 mg, Hyoscyamine Sulfate 0.12 mg, Rx Only, 100-count bottle, Manufactured For: Llorens Pharmaceutical Corp., International Division, Miami, FL 33166. NDC: 54859-701-10 recalled?

Yes. FDA published recall D-0081-2018 on November 22, 2017. Reported hazard: Superpotent Drug: Subpotent Drug. FDA analysis found this product to be Out of Specification for assay which could result in either Subpotent and/or Superpotent tablets.

What should I do if I have this product?

Voluntary: Firm initiated · Letter